1. Home
  2. NRIX vs PD Comparison

NRIX vs PD Comparison

Compare NRIX & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.17

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo PagerDuty Inc.

PD

PagerDuty Inc.

HOLD

Current Price

$11.22

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
PD
Founded
2009
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.2B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
NRIX
PD
Price
$19.17
$11.22
Analyst Decision
Strong Buy
Hold
Analyst Count
13
10
Target Price
$29.08
$17.10
AVG Volume (30 Days)
1.2M
1.9M
Earning Date
02-12-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.63
Revenue
$83,687,000.00
$489,207,000.00
Revenue This Year
$59.40
$8.16
Revenue Next Year
N/A
$3.75
P/E Ratio
N/A
$6.61
Revenue Growth
48.32
7.01
52 Week Low
$8.18
$10.66
52 Week High
$22.50
$20.00

Technical Indicators

Market Signals
Indicator
NRIX
PD
Relative Strength Index (RSI) 55.82 34.81
Support Level $18.12 $10.66
Resistance Level $19.50 $12.75
Average True Range (ATR) 1.05 0.41
MACD -0.08 -0.12
Stochastic Oscillator 67.22 22.71

Price Performance

Historical Comparison
NRIX
PD

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

Share on Social Networks: